Charles River Laboratories International (CRL) has collaborated with Australian biotechnology firm Magellan Stem Cells to advance the development and clinical progress of Magellan’s regenerative medicine candidate, Zelestrocel.
Life science tools and diagnostics provider Bio-Techne Corporation has opened a new manufacturing facility in Bristol, UK, dedicated to good manufacturing practice (GMP) grade small molecules.
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.
Cellares and Papillon Therapeutics have entered a partnership to automate the manufacturing of PPL-001, an investigational therapy developed by the latter for Friedreich’s ataxia (FA), a rare inherited neurodegenerative disorder.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta Pharma’s C-CAR168.
Cellares and Sonoma Biotherapeutics have entered a collaboration to automate the manufacturing of the latter’s lead cell therapy programme, SBT-77-7101, using the Cellares Cell Shuttle platform.
Aurion Biotech has raised $120m from biotech and ophthalmology investors to progress its cell therapy programme for corneal edema secondary to endothelial dysfunction.
Enveric Biosciences has announced that it has signed an exclusive, perpetual licensing agreement with Diverse Biotech to develop new molecules for the treatment of cancer and other debilitating diseases.
Bioscience researchers at GE Research have begun an in-depth study to better understand the impact of the Covid-19 virus on the lungs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.